These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38861891)

  • 21. Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog.
    Gydesen S; Andreassen KV; Hjuler ST; Hellgren LI; Karsdal MA; Henriksen K
    Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E598-E607. PubMed ID: 28292761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.
    Wu Y; Ji T; Lv J; Wang Z
    Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice.
    Hansen HH; Grønlund RV; Baader-Pagler T; Haebel P; Tammen H; Larsen LK; Jelsing J; Vrang N; Klein T
    Sci Rep; 2021 Apr; 11(1):8060. PubMed ID: 33850212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats.
    Zhang Y; Rahematpura S; Ragnini KH; Moreno A; Stecyk KS; Kahng MW; Milliken BT; Hayes MR; Doyle RP; Schmidt HD
    Neuropharmacology; 2021 Jul; 192():108599. PubMed ID: 33965397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.
    Kanoski SE; Rupprecht LE; Fortin SM; De Jonghe BC; Hayes MR
    Neuropharmacology; 2012 Apr; 62(5-6):1916-27. PubMed ID: 22227019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
    de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
    Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.
    Mul JD; Begg DP; Barrera JG; Li B; Matter EK; D'Alessio DA; Woods SC; Seeley RJ; Sandoval DA
    Am J Physiol Regul Integr Comp Physiol; 2013 Jul; 305(1):R68-77. PubMed ID: 23616105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats.
    Reidelberger RD; Haver AC; Apenteng BA; Anders KL; Steenson SM
    Obesity (Silver Spring); 2011 Jan; 19(1):121-7. PubMed ID: 20559304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies.
    Jiang P; Zeng Y; Yang W; Li L; Zhou L; Xiao L; Li Y; Gu B; Li X; Li J; Li W; Guo L
    Biomed Pharmacother; 2024 May; 174():116485. PubMed ID: 38518602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.
    Pei Z; Zhou D; Yan J; Wang S; Yang X; Pei Z
    Life Sci; 2020 Jul; 253():117651. PubMed ID: 32304764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses high fat diet-induced obesity and glucose intolerance in Sprague-Dawley rats.
    Hata T; Mera Y; Tadaki H; Kuroki Y; Kawai T; Ohta T; Kakutani M
    Diabetes Obes Metab; 2011 May; 13(5):446-54. PubMed ID: 21255216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
    Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
    J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.
    Pickford P; Lucey M; Rujan RM; McGlone ER; Bitsi S; Ashford FB; Corrêa IR; Hodson DJ; Tomas A; Deganutti G; Reynolds CA; Owen BM; Tan TM; Minnion J; Jones B; Bloom SR
    Mol Metab; 2021 Sep; 51():101242. PubMed ID: 33933675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of GLP-1 Receptor Agonists in the Cardiometabolic Complications in a Rat Model of Postmenopausal PCOS.
    Torres Fernandez ED; Huffman AM; Syed M; Romero DG; Yanes Cardozo LL
    Endocrinology; 2019 Dec; 160(12):2787-2799. PubMed ID: 31593246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys.
    Jensen MH; Sanni SJ; Riber D; Holst JJ; Rosenkilde MM; Sparre-Ulrich AH
    Mol Metab; 2024 Oct; 88():102006. PubMed ID: 39128651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined loss of GLP-1R and Y2R does not alter progression of high-fat diet-induced obesity or response to RYGB surgery in mice.
    Boland BB; Mumphrey MB; Hao Z; Townsend RL; Gill B; Oldham S; Will S; Morrison CD; Yu S; Münzberg H; Rhodes CJ; Trevaskis JL; Berthoud HR
    Mol Metab; 2019 Jul; 25():64-72. PubMed ID: 31126840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice.
    He M; Su H; Gao W; Johansson SM; Liu Q; Wu X; Liao J; Young AA; Bartfai T; Wang MW
    PLoS One; 2010 Dec; 5(12):e14205. PubMed ID: 21151924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.
    Larsen PJ; Fledelius C; Knudsen LB; Tang-Christensen M
    Diabetes; 2001 Nov; 50(11):2530-9. PubMed ID: 11679431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.